


Accepted Manuscript

Title: AEROSOL FUROSEMIDE FOR DYSPNEA:
HIGH-DOSE CONTROLLED DELIVERY DOES NOT
IMPROVE EFFECTIVENESS

Authors: Robert B. Banzett, Richard M. Schwartzstein, Robert
W. Lansing, Carl R. O'Donnell



PII: S1569-9048(17)30154-4
DOI: <http://dx.doi.org/10.1016/j.resp.2017.08.010>
Reference: RESPNB 2849

To appear in: *Respiratory Physiology & Neurobiology*

Received date: 14-5-2017
Revised date: 14-8-2017
Accepted date: 15-8-2017

Please cite this article as: Banzett, Robert B., Schwartzstein, Richard M., Lansing, Robert W., O'Donnell, Carl R., AEROSOL FUROSEMIDE FOR DYSPNEA: HIGH-DOSE CONTROLLED DELIVERY DOES NOT IMPROVE EFFECTIVENESS. *Respiratory Physiology and Neurobiology* <http://dx.doi.org/10.1016/j.resp.2017.08.010>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

AEROSOL FUROSEMIDE FOR DYSPNEA: HIGH-DOSE CONTROLLED DELIVERY DOES NOT IMPROVE EFFECTIVENESS

Robert B Banzett^{1,2}, Richard M Schwartzstein^{1,2}, Robert W Lansing¹, Carl R O'Donnell^{1,2}

¹ Division of Pulmonary, Critical Care, and Sleep Medicine
Beth Israel Deaconess Medical Center
Boston, MA, 02215.

²Department of Medicine
Harvard Medical School
Boston, MA, 02115 USA

HIGHLIGHTS

- We tested hypotheses that might explain failure of aerosol furosemide to alleviate experimental dyspnea.
- Control of aerosol delivery did not increase the proportion of subjects who responded.
- Doubling furosemide dose did not increase the proportion of subjects who responded..
- Response variation was partially explained by variation of response to large breaths.

Supported by NIH-NR12009

ABSTRACT

Published studies have shown great variability in response when aerosolized furosemide has been tested as a palliative treatment for dyspnea. We hypothesized that a higher furosemide dose with controlled aerosol administration would produce consistent dyspnea relief. We optimized deposition by controlling inspiratory flow (300-500 ml/s) and tidal volume (15% predicted vital capacity) while delivering 3.4 micron aerosol from either saline or 80 mg of furosemide. We induced dyspnea in healthy subjects by varying inspired P_{CO_2} while restricting minute ventilation. Subjects rated “Breathing Discomfort” on a Visual Analog Scale (BDVAS, 100% Full Scale = intolerable). At the $PETCO_2$ producing 60% BDNAS pre-treatment, furosemide produced a clinically meaningful reduction of BDNAS (i.e., > 20%FS) in 5/11 subjects; saline reduced dyspnea in 3/11 subjects; neither treatment worsened dyspnea in any subject. Furosemide and saline treatment effects were not statistically different. There were no significant adverse events. Higher furosemide dose and controlled delivery did not improve consistency of treatment effect compared with prior studies.

Keywords: Dyspnea, Furosemide, Palliative care, Symptom management

Download English Version:

<https://daneshyari.com/en/article/5594039>

Download Persian Version:

<https://daneshyari.com/article/5594039>

[Daneshyari.com](https://daneshyari.com)